JP2015521041A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521041A5
JP2015521041A5 JP2015511948A JP2015511948A JP2015521041A5 JP 2015521041 A5 JP2015521041 A5 JP 2015521041A5 JP 2015511948 A JP2015511948 A JP 2015511948A JP 2015511948 A JP2015511948 A JP 2015511948A JP 2015521041 A5 JP2015521041 A5 JP 2015521041A5
Authority
JP
Japan
Prior art keywords
pkn3
inhibitor
vegfr1
suffering
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521041A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/001441 external-priority patent/WO2013170960A1/en
Publication of JP2015521041A publication Critical patent/JP2015521041A/ja
Publication of JP2015521041A5 publication Critical patent/JP2015521041A5/ja
Pending legal-status Critical Current

Links

JP2015511948A 2012-05-16 2013-05-15 Ｐｋｎ３阻害剤投与のためのバイオマーカーとしてのｖｅｇｆｒ１の使用 Pending JP2015521041A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12003888.0 2012-05-16
EP12003888 2012-05-16
PCT/EP2013/001441 WO2013170960A1 (en) 2012-05-16 2013-05-15 Use of vegfr1 as a biomarker for pkn3 inhibitor administration

Publications (2)

Publication Number Publication Date
JP2015521041A JP2015521041A (ja) 2015-07-27
JP2015521041A5 true JP2015521041A5 (enExample) 2016-07-07

Family

ID=48446240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511948A Pending JP2015521041A (ja) 2012-05-16 2013-05-15 Ｐｋｎ３阻害剤投与のためのバイオマーカーとしてのｖｅｇｆｒ１の使用

Country Status (4)

Country Link
US (2) US9133515B2 (enExample)
EP (1) EP2849771A1 (enExample)
JP (1) JP2015521041A (enExample)
WO (1) WO2013170960A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016083623A1 (en) * 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Means for the treatment of pre-eclampsia
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084987C (en) 1990-06-11 2007-02-13 Gilead Sciences, Inc. Nucleic acid ligands
US20040220128A1 (en) * 1995-10-26 2004-11-04 Sirna Therapeutics, Inc. Nucleic acid based modulation of female reproductive diseases and conditions
WO1998008856A2 (de) 1996-08-30 1998-03-05 Fuerste Jens Peter Spiegelselektion und spiegelevolution von nucleinsäuren
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
DK1536827T3 (da) 2002-08-14 2009-04-20 Silence Therapeutics Ag Anvendelse af proteinkinase N-beta
CN101490253A (zh) 2006-07-21 2009-07-22 赛伦斯治疗公司 用于抑制蛋白激酶3表达的方法

Similar Documents

Publication Publication Date Title
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
LT3321276T (lt) Sulieti baltymai, skirti metabolinių sutrikimų gydymui
EP2760371A4 (en) VENTRICULAR TRANSCATHETER RECONSTRUCTION STRUCTURES, METHODS AND SYSTEMS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE AND OTHER SUFFERING
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
LT3303307T (lt) Nauji gadolinio chelatiniai junginiai, skirti naudoti magnetinio rezonanso tomografijoje
LT3206716T (lt) Kanabinoidų panaudojimas atoninių traukulių gydymui, esant lennox-gastaut' sindromui
CL2015001442A1 (es) Metodo para tratar enfermedades pulmonares que comprende el uso de compuestos derivados del acido obeticolico.
IL231228A0 (en) Bicyclic heterocycle derivatives for the treatmen t of pulmonary arterial hypertension
IL235261B (en) Antibodies against claudin 18.2 useful in cancer diagnosis
HUE049323T2 (hu) Hízósejt-stabilizálók tüdõbetegség kezelésére
PT2989110T (pt) Derivados de tamoxifeno para o tratamento de doenças neoplásicas, especialmente com nível elevado de proteína her2
ZA201403549B (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
EA201500997A1 (ru) Терапевтические применения эмпаглифлозина
WO2012112315A3 (en) Methods for diagnosis of kawasaki disease
HUE045724T2 (hu) GRPR antagonisták GRPR-pozitív rák kimutatására, diagnózisára és kezelésére
EA201590359A1 (ru) Лечение ревматоидного артрита
CY2020015I2 (el) Σικλεσονιδη για τη θεραπεια της νοσου των αεραγωγων σε αλογα
EP2994134A4 (en) Methods of administering dantrolene for the acute treatment of cardiac arrhythmias
HK1212713A1 (zh) Vegfr1抗體的治療性用途
IL264382B (en) Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein
HUE053229T2 (hu) FK506 alkalmazása pulmonális artériás hipertenzió kezelésére
EP2956475A4 (en) MODIFIED INGAP PEPTIDES FOR THE TREATMENT OF DIABETES
JP2015521041A5 (enExample)
BR112017021413A2 (pt) anticorpos anti-flt-1 no tratamento da displasia broncopulmonar.